Stockreport

Stoke Therapeutics (STOK) Up on Upbeat Dravet Syndrome Study Data [Yahoo! Finance]

Stoke Therapeutics, Inc.  (STOK) 
Last stoke therapeutics, inc. earnings: 11/12 08:00 am Check Earnings Report
PDF investigational candidate,STK-001, in children and adolescents aged two to 18 years with Dravet syndrome. STK-001 is Stoke Therapeutics' novel proprietary antisense ol [Read more]